Back to Search Start Over

Prognostic Impact of Mitral Regurgitation Before and After Transcatheter Aortic Valve Replacement in Patients With Severe Low‐Flow, Low‐Gradient Aortic Stenosis

Authors :
Germano Junior Ferruzzi
Angelo Silverio
Arturo Giordano
Nicola Corcione
Michele Bellino
Tiziana Attisano
Cesare Baldi
Alberto Morello
Giuseppe Biondi‐Zoccai
Rodolfo Citro
Carmine Vecchione
Gennaro Galasso
Source :
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 17 (2023)
Publication Year :
2023
Publisher :
Wiley, 2023.

Abstract

Background There is little evidence about the prognostic role of mitral regurgitation (MR) in patients with low‐flow, low‐gradient aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). The aim of this study was to assess the prevalence and outcome implications of MR severity in patients with low‐flow, low‐gradient aortic stenosis undergoing TAVR, and to evaluate whether MR improvement after TAVR could influence clinical outcome. Methods and Results This study included consecutive patients with low‐flow, low‐gradient aortic stenosis undergoing TAVR at 2 Italian high‐volume centers. The study population was categorized according to the baseline MR severity and to the presence of MR improvement at discharge. The primary outcome was the composite of all‐cause death and hospitalization for worsening heart failure up to 1 year. The study included 268 patients; 57 (21%) patients showed MR >2+. Patients with MR >2+ showed a lower 1‐year survival free from the primary outcome (P2+ was an independent predictor of the primary outcome (P2+, MR improvement was reported in 24 (44%) cases after TAVR. The persistence of MR was associated with a significantly reduced survival free from the primary outcome, all‐cause death, and heart failure hospitalization up to 1 year. Conclusions In this study, the presence of moderately severe to severe MR in patients with low‐flow, low‐gradient aortic stenosis undergoing TAVR portends a worse clinical outcome at 1 year. TAVR may improve MR severity in nearly half of the patients, resulting in a potential outcome benefit after discharge.

Details

Language :
English
ISSN :
20479980 and 85792438
Volume :
12
Issue :
17
Database :
Directory of Open Access Journals
Journal :
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Publication Type :
Academic Journal
Accession number :
edsdoj.b7383343f419481d857924386bd5df3e
Document Type :
article
Full Text :
https://doi.org/10.1161/JAHA.123.029553